Nordic pharmaceutical company Pharmaco forges further into Northern
Europe unveiling new sales activities in Sweden to cut into the
growing generic pharmaceutical market there.
Misssouri-based medical genomics company GenoMed will link up with
Malaysian company PhenoMed, encouraged by the Malaysian government
currently keen to push biotechnology advances in the country.
Solutia has launched an offensive on the outsourced peptide
synthesis market with the formation of a new business group in
Switzerland focusing on the sector.
The market for protein and DNA purification kits is maturing, and
the pace of technological innovation has slowed, leaving dozens of
companies jostling for market share.
An Australian company claims to have successfully achieved the
simultaneous disabling of multiple genes through its RNA
interference (RNAi) technology.
Amersham Biosciences has filed a lawsuit against PerkinElmer
alleging that the latter has infringed on two of Amersham's patents
for a reagent technology used in the development of new drugs.
Tecan's third-quarter results reveal a mixed picture across the
group, with proteomics/genomics put in a good good performance but
drug discovery sales fell by a quarter.
AstraZeneca is roundly rebuked by The Lancet in an editorial that
describes the firm's development of its new cholesterol-lowering
drug Crestor as a "triumph of marketing over science". Chief
executive Sir Tom McKillop...
Schott Nexterion, a supplier of DNA microarrays and the youngest
subsidiary of the Schott Group, has taken over the microarrays
business division of Quantifoil Micro Tools.
October has seen a rush by US biotechnology companies to list on
the stock markets, bringing to an end an Initial Public Offering
(IPO) drought lasting more than 18 months. Is Europe destined to
follow?
Biotechnology company Biovitrum has established a new business
unit, Biovitrum Biopharmaceuticals, to strengthen its position as a
supplier of process development and contract manufacture of
recombinant proteins. The move follows...
Switzerland's Integra Biosciences extends its CELLine range of
disposable bioreactor vessels with a new version intended for use
with adherent cell lines.
PerkinElmer sees the benefit of a cost-cutting effort in its
third-quarter results as net income rises 45 per cent, but
biopharma puts in a lacklustre performance.
